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Background: Skeletal muscle is the most abundant tissue in the body and is a major source of total energy
expenditure in mammals. Skeletal muscle consists of fast and slow fiber types, which differ in their energy
usage, contractile speed, and force generation. Although skeletal muscle plays a major role in whole body metabolism,
the transcription factors controlling metabolic function in muscle remain incompletely understood. Members of the
myocyte enhancer factor 2 (MEF2) family of transcription factors play crucial roles in skeletal muscle development and
function. MEF2C is expressed in skeletal muscle during development and postnatally and is known to play roles in
sarcomeric gene expression, fiber type control, and regulation of metabolic genes.
Methods: We generated mice lacking Mef2c exclusively in skeletal muscle using a conditional knockout approach and
conducted a detailed phenotypic analysis.
Results: Mice lacking Mef2c in skeletal muscle on an outbred background are viable and grow to adulthood, but they
are significantly smaller in overall body size compared to control mice and have significantly fewer slow fibers. When
exercised in a voluntary wheel running assay, Mef2c skeletal muscle knockout mice aberrantly accumulate glycogen in
their muscle, suggesting an impairment in normal glucose homeostasis. Consistent with this notion, Mef2c skeletal
muscle knockout mice exhibit accelerated blood glucose clearance compared to control mice.
Conclusions: These findings demonstrate that MEF2C function in skeletal muscle is important for metabolic
homeostasis and control of overall body size.
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Skeletal muscle comprises approximately 40% of total
body mass and accounts for more than 30% of the energy
expenditure in the mouse. As a result, skeletal muscle
plays an important role in whole-body energy homeostasis
[1,2]. During exercise and insulin stimulation, skeletal
muscle is the primary tissue for glucose uptake, disposal,
and storage as glycogen for energy reserves [1,3]. In turn,
muscle can use glycogen to produce energy through gly-
cogenolysis, the breakdown of glycogen into glucose [4].
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unless otherwise stated.contributor to the development of insulin resistance since
muscle is the most abundant insulin-sensitive tissue in
the body. Insulin resistance leads to decreased insulin
signaling and, in turn, to decreased glucose transport into
muscle [5].
Sarcomeres are the functional units of muscle fibers.
Sarcomeres are composed of repeating units of thick
myosin filaments and thin actin filaments [6]. Depending
on the type of myosin in the muscle fiber, contraction can
be slow or fast [7]. Despite having a stereotyped fiber type
pattern established during development, adult myofibers
can switch their fiber type in response to cues such as ex-
ercise, contraction, or motor neuron activity [7-9]. Type I
(slow) fibers utilize oxidative metabolism as their primary
energy source, are rich in mitochondria, and are slow to
fatigue. In contrast, type II (fast) fibers utilize glycolysisral. This is an Open Access article distributed under the terms of the Creative
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The proportion of fast and slow fiber types play a pivotal
role in whole-body metabolism: a predominance of slow
fibers leads to resistance to diet-induced obesity and an in-
crease in fast fibers in obese mice leads to reduced body
weight and fat mass [11,12].
Myocyte enhancer factor 2 (MEF2) proteins function
as key transcriptional regulators of skeletal muscle devel-
opment, sarcomeric gene expression, fiber type control,
and glucose uptake metabolism [13-17]. MEF2 proteins
undergo extensive posttranslational modifications and
cofactor interactions, allowing them to function as either
activators or repressors of transcription [13]. Mef2c is
the earliest Mef2 gene expressed in skeletal muscle [18].
Mice that lack Mef2c die by E10 due to cardiovascular
defects [19,20], precluding studies on the role of MEF2C
in skeletal muscle in germline knockout mice. Condi-
tional inactivation of Mef2c in skeletal muscle on an in-
bred C57BL/6 background has been reported to cause
defects in sarcomere integrity and postnatal muscle mat-
uration [21]. Consistent with these observations, the
Mef2c paralogs in zebrafish, mef2ca and mef2cb, function
in sarcomere formation [22].
In this study, we used a conditional knockout approach
in mice to delete MEF2C function exclusively in skeletal
muscle on an outbred background. Consistent with prior
studies [21,23], we found that MEF2C is required for nor-
mal fiber type composition. On the other hand, in contrast
to previous studies [21], we found no evidence of lethality,
and Mef2c skeletal muscle knockout mice survived nor-
mally. We found that mice lacking Mef2c in skeletal
muscle have impaired overall body growth and abnormal
glucose uptake and metabolism, and we found that mice
lacking MEF2C in skeletal muscle display abnormal glyco-
gen accumulation in muscle in response to exercise. Over-
all, our findings highlight a novel metabolic function for
MEF2C in skeletal muscle, where it is required for glucose
metabolism, glycogen utilization, and energy homeostasis.
Methods
Mice
Mef2c+/−, Mef2cflox/flox, and Mef2c-73k-Cre mice have
been described [20,24,25]. All mice from litters intended
to generate Mef2c skeletal muscle knockout mice
(Mef2cSkMKO) were weighed on the evening of the day of
birth and this was designated as P1. Overall body weight
was also measured on P4, P7, P10, P14, P21, P28, and
P52. Tibia length was measured at 52 days of age by dis-
secting the tibia and measuring the length using a vernier
caliper. Voluntary exercise assays were conducted as de-
scribed previously [26]. For glucose tolerance tests, 10-
week-old male mice were fasted for 16 h overnight with
ad lib access to water. Blood glucose measurements were
then taken for a baseline reading (0 min) by nicking thetail with a razor blade and using a blood glucose meter
(FreeStyle, Therasense, 99073-0110-01, Abbott Diabetes
Care, Alameda, USA). Mice were then administered a
bolus injection of glucose (1 g glucose/kg body weight).
Blood glucose readings were then taken at 15, 30, 60, and
120 min. Euthanasia was performed by carbon dioxide as-
phyxiation followed by cervical dislocation. Genotypes
were determined by Southern blot using genomic tail or
embryonic yolk sac DNA. All experiments using animals
complied with federal and institutional guidelines and
were reviewed and approved by the UCSF Institutional
Animal Care and Use Committee.
In situ hybridization, histology, and
immunohistochemistry
Whole-mount in situ hybridization was performed as
previously described [27]. Mef2c antisense RNA in situ
probe was generated from the plasmid pBS-MEF2C. In
brief, a 208 bp fragment from the Mef2c cDNA was cloned
into plasmid pBluescript-SKII(+) and an antisense probe
was generated by linearizing the plasmid with HindIII and
transcribing with T3 polymerase.
For skeletal muscle histology, muscles were isolated from
mice and immediately embedded in OCT embedding
medium (Tissue Tek, Thermo Fisher Scientific, Waltham,
USA) and frozen in liquid nitrogen-cooled isopentane.
Fresh frozen embedded muscles were then cryosectioned
at a thickness of 10 μm and stained with hematoxylin and
eosin (H & E) as previously described [28]. For immuno-
histochemistry, sections were fixed in 4% paraformalde-
hyde for 10 min and blocked in 3% normal goat serum in
PBS for 1 h at room temperature. Sections were then incu-
bated with mouse monoclonal anti-skeletal muscle myosin
(MY-32, Sigma M4276, Sigma, St. Louis, USA) followed by
incubation with Alexa Fluor 594 anti-mouse (Molecular
Probes, Invitrogen, Life Technologies, Grand Island, USA).
Both antibodies were used at a concentration of 1:300 in
3% normal goat serum and incubated for 1 h at room
temperature. Sections were mounted using Slow-Fade
Gold antifade reagent with DAPI (Invitrogen) and photo-
graphed on a fluorescence microscope. Fiber type meas-
urement was determined using sections stained for MY32.
All fibers in a 10× field from two different sections from
throughout the length of the soleus muscle were counted
to determine the number of Type I and Type II fibers. Tis-
sues were prepared for electron microscopy as described
previously with only minor modifications [29]. For tolui-
dine blue staining, 1 μm sections were cut and stained with
1% toluidine blue (Sigma 89640) in 1% sodium borate.
Periodic acid Schiff’s staining and glycogen content
quantification
Periodic acid Schiff ’s (PAS) staining for glycogen was done
on fresh frozen 10-μm-thick sections from quadriceps
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fixed in Carnoy’s fixative (60% ethanol, 30% chloroform,
10% acetic acid) for 5 min, followed by rinsing three times
with water. Sections were immersed in 0.5% periodic acid
(Sigma P7875) for 5 min, followed by rinsing with water
four times and then transferred to Schiff ’s solution (Sigma
3952016) for 10 min, followed by rinsing in running tap
water for 10 min. Sections were mounted using Cytoseal
60 mounting medium (Richard-Allan Scientific 8310-16).
Total glycogen content in muscle was quantified using
an adaptation of a previously described method [31]. In
brief, 30 mg of frozen gastrocnemius muscle was dis-
solved in 1 ml 5 N KOH in a boiling water bath, then
0.2 ml of saturated sodium sulfate and 1.5 ml ethanol
were added. Samples were spun at 2,000 × g for 10 min
at 4°C and the pelleted material was resuspended in 0.5
ml 2 N HCl and incubated in a boiling water bath for 2
to 2.5 h. Samples were cooled and neutralized to pH 6
to 8 with 4 N KOH in 0.1 M triethanolamine. Glycogen
content was determined by measuring the glucose re-
leased from glycogen using a glucose assay kit as recom-
mended by the manufacturer (Sigma GAHK20).
RNA isolation, cDNA synthesis, and quantitative and
semi-quantitative RT-PCR
RNA was isolated from the quadriceps muscle using the
TRIzol protocol and purified using the RNeasy Mini Kit
and RNA clean-up protocol (Qiagen, Valencia, USA),
according to the manufacturer’s recommendations. To
synthesize cDNA, 2 μg of total RNA was used per cDNA
reaction using the Omniscript Reverse Transcriptase
protocol (Qiagen). Quantitative real-time RT-PCR (qPCR)
was performed on an ABI 7500 Real-Time PCR machine
using SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, USA). The following primers were used
in both the semi-quantitative and qPCR: Mef2cF, 5′-
GGCCATGGTACACCGAGTACAACGAGC-3′; Mef2cR,
5′-GGGGATCCCTGTGTTACCTGCACTTGG-3′; prod-
uct size: 387 bp [32]. L7F, 5′-GGAGCTCATCTATGAGA
AGGC-3′; L7R, 5′-AAGACGAAGGAGCTGCAGAAC-
3′; product size: 202 bp [33].
Results
Generation of skeletal muscle-specific Mef2c conditional
knockout mice
We inactivated Mef2c exclusively in skeletal muscle using
a conditional gene targeting approach by crossing a skel-
etal muscle-specific Cre transgenic mouse line, Mef2c-
73k-Cre [24], to a mouse harboring a floxed Mef2c allele
[25] according to the strategy outlined in Figure 1A. Skel-
etal muscle-specific Mef2c knockout mice (Mef2cSkMKO)
were born at predicted Mendelian frequency (Figure 1B)
and were viable and fertile and appeared overtly normal
(data not shown). To determine the efficiency of Mef2cgene inactivation in skeletal muscle, we examined the ex-
pression of Mef2c within the skeletal muscle in Mef2cflox/+
mice, hereafter referred to as control (ctl) mice, and
Mef2cSkMKO mice (cko) by in situ hybridization (Figure 1C,
D,E,F). At E9.5, control embryos showed strong expression
of Mef2c in the myotomal compartment of the somites
(Figure 1C). Mef2c expression in the skeletal muscle of the
limbs and in intercostal muscles was also readily apparent
in control embryos at E13.5 (Figure 1E). By contrast, Mef2c
expression was disrupted in Mef2cSkMKO embryos such
that it was not detectable by in situ hybridization at any
stage examined, including E9.5 and E13.5 (Figure 1D,F).
Mef2c transcripts were not detectable in the quadriceps
muscle in adultMef2cSkMKO mice by RT-PCR under condi-
tions where Mef2c expression was readily detectable in
control mice (Figure 1G). When quantified by qPCR,
Mef2c transcripts were approximately 50-fold more
abundant in quadriceps muscle tissue from control
mice than from Mef2cSkMKO mice (Figure 1H). These
results indicate a near complete inactivation of Mef2c in
skeletal muscle using our conditional approach.MEF2C is required in skeletal muscle for normal growth
of mice
Mice lacking Mef2c function in skeletal muscle appeared
overtly normal and showed no decrease in viability com-
pared to littermate controls. Interestingly, however,
Mef2cSkMKO mice weighed significantly less than age-
and sex-matched controls. In male mice, this difference
became apparent by postnatal day 10 (P10) and contin-
ued until early adulthood (Figure 2). The difference in
weight between control and Mef2cSkMKO mice reflected
a change in overall body size, which was also apparent
when the length of the tibia was measured in control
and Mef2cSkMKO mice. The tibia length in Mef2cSkMKO
mice was significantly smaller than age- and sex-matched
control mice at 52 days of age (control mice, 176.14 mm±
2.36 mm, n = 7; Mef2cSkMKO mice, 168.92 mm± 1.95 mm,
n = 12; p = 0.034). Taken together, these data show that
overall body size and growth is reduced when Mef2c is ab-
sent from skeletal muscle.MEF2C is required for normal fiber type composition in
skeletal muscle
Morphological analyses of skeletal muscle from Mef2cSkMKO
mice by H & E staining did not demonstrate any alter-
ations in the patterning or development of skeletal muscle
fibers in muscle from Mef2cSkMKO mice compared to
controls, and centrally located nuclei were not observed
(Figure 3A,B). These observations suggest that muscle de-
velopment, sarcomere assembly, and muscle ultrastruc-
ture were grossly normal in mice lacking Mef2c in skeletal
muscle.
Figure 1 Generation of skeletal muscle-specific Mef2c knockout mice. (A) Schematic depicting the strategy for deleting Mef2c from skeletal
muscle. Mef2c-73k-CreTg/0; Mef2c+/− males were crossed to Mef2cflox/flox female mice to generate control (Mef2cflox/+) and Mef2c skeletal muscle
knockout mice (Mef2cSkMKO), which have the genotype Mef2c-73k-CreTg/0; Mef2cflox/− (shown in red text). (B) All genotypes were observed at
expected Mendelian ratios (χ2 = 0.328, 3 d.f.). (C-F) Mef2c was readily detected in somites of control mice at E9.5 (C) and in skeletal muscles of
control mice at E13.5 (E). In contrast, Mef2c transcripts were not detected by in situ hybridization in somites at E9.5 (D) or in skeletal muscles at E13.5
(F) in Mef2cSkMKO mice. (G) Semi-quantitative RT-PCR analyses of three control and three Mef2cSkMKO adult quadriceps muscle detected Mef2c
transcripts in control but not in Mef2cSkMKO. L7 transcripts were similarly detected in samples from all six mice. (H) Expression of Mef2c in
adult quadriceps muscle was analyzed by quantitative real-time RT-PCR (qPCR). Mef2cSkMKO mice showed more than 95% reduction in
Mef2c transcripts compared to control muscle (n = 3; **p < 0.01). Values shown are the mean + standard deviation.
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slow, oxidative type I fibers is known to be regulated by
MEF2 proteins [23,34,35]. Therefore, we examined the ex-
pression of fast myosin isoforms in the soleus muscle of
control and Mef2cSkMKO mice (Figure 3C,D). The soleus
muscle is one of the few muscles in mice with a large pro-
portion of slow fibers [36]. Staining sections of soleus
muscle with MY32, an antibody that recognizes all fast
myosin isoforms, showed a significantly higher percentage
of fast fibers in Mef2cSkMKO mice than in control mice
(Figure 3C,D, red immunofluorescence). Quantification offast and slow fibers indicated that mice lacking Mef2c
in skeletal muscle had a significant decrease in the per-
centage of slow fibers in the soleus muscle (Figure 3E).
These results are consistent with a role for MEF2C in
maintaining fiber type balance, as has been previously re-
ported [23,34,35].
Excess glycogen accumulation in skeletal muscle of
Mef2cSkMKO mice in response to exercise
Because Mef2cSkMKO mice have a reduced number of type
I (slow) fibers, we examined skeletal muscle function by
Figure 2 Mef2c function in skeletal muscle is required for
normal growth of mice. Body weight measurements of male mice
at postnatal days (P) 1, 4, 7, 10, 14, 21, 28, and 52 (n = 7 to 46) show
a significant difference in body weight between control (ctl) and
Mef2cSkMKO (cko) by P10. *p < 0.05; **p < 0.01; ***p < 0.001. Values
shown are mean + standard deviation.
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exercise assay (Figure 4). Mef2cSkMKO mice showed no sig-
nificant change in the distance run or time spent running
when compared to control mice despite a reduction in
slow fibers (Figure 4A,B).Figure 3 Mef2c is required for normal fiber type composition in skele
(cko) male mice at 52 days of age were analyzed for morphology and fiber
on control and Mef2cSkMKO muscle sections at 10× magnification showed no ov
staining for fast myosin (MY32) for fiber type identification from control
greater percentage of fast fibers in Mef2cSkMKO muscles than in controls
unstained. (E) Quantification of slow/type I fibers as detected by MY32
sections showed a significant decrease in the number of slow fibers in
(32.8% ± 0.8% slow); n = 8; ***p < 0.001. Values shown are the mean + staPrevious studies have reported a role for MEF2C in
sarcomere architecture [21]. Therefore, we examined
Mef2cSkMKO and control mice for sarcomeric structural
defects at baseline and following a weeklong voluntary
exercise regime by electron microscopy (Figure 5). Non-
exercised (No Run) control and Mef2cSkMKO mice had
well-organized sarcomeres and essentially no difference
in the ultrastructure of the muscle (Figure 5A,D). Analyses
of post-exercise (Run) skeletal muscle demonstrated an in-
creased number of mitochondria in both control and
Mef2cSkMKO mice compared to mice that had not been
subjected to voluntary exercise (Figure 5B,E). This was an
expected result since increased mitochondrial biogenesis
is a normal response to exercise [37]. Importantly, we ob-
served the presence of large vacuolar inclusion bodies in
the soleus muscle of Mef2cSkMKO mice following 7 days of
voluntary exercise (Figure 5E, arrowheads). These vacu-
oles were present throughout the muscle and qualitatively
appeared to contain a granular material (Figure 5E). Tolui-
dine blue staining also suggested the presence of inclusions,
as well as centrally located nuclei, in the muscle fibers of
exercised Mef2cSkMKO mice but not in control muscle
(Figure 5C,F). These results support a role for MEF2C in
maintaining muscle in a normal healthy state in response
to a period of extended exercise.
The granular vacuoles in Mef2cSkMKO mice superfi-
cially resembled glycogen deposits. Therefore, we exam-
ined glycogen levels in soleus muscles from control and
Mef2cSkMKO mice pre- and post-exercise (Figure 6). PAS
staining for glycogen showed that control andMef2cSkMKOtal muscle. Soleus muscle sections from control (ctl) and Mef2cSkMKO
type. (A, B) Hematoxylin and eosin stain for morphological analysis
ert differences in skeletal muscle morphology. (C, D) Immunofluorescence
and Mef2cSkMKO muscle sections at 10× magnification showed a
. Red staining marks fast/type II fibers; slow/type I fibers are
immunofluorescence staining in control and Mef2cSkMKO muscle
Mef2cSkMKO mice (25.4% ± 1.2% slow) compared to control mice
ndard deviation.
Figure 4 Mef2c function in skeletal muscle is not required for
voluntary exercise capability. Six-week-old male control (ctl) and
Mef2cSkMKO (cko) mice were tested for their ability to run on an
exercise running wheel for 1 week, following a 3-day training
period, and distance (A) and time (B) run nightly were measured. No
significant differences in either parameter were recorded; n = 8 to 12.
Values shown are mean + standard deviation.
Figure 5 Loss of Mef2c function in skeletal muscle results in
exercise-induced inclusions in muscle. (A, B, D, E) Ultrastructural
analysis of the soleus muscle from exercised (Run) and unexercised
(No Run) mice was determined by electron microscopy (EM) at
8,000× magnification. (A, D) Unexercised control (A) and Mef2cSkMKO
(D) mice each displayed well-organized sarcomeres prior to exercise.
(B, E) After exercise, both control and Mef2cSkMKO mice had an
increase in mitochondria (arrows). Exercised Mef2cSkMKO mice also
had increased accumulation of large vacuolar inclusion bodies
(arrowheads) in between the sarcomeres (E). (C, F) Sections from
exercised control and Mef2cSkMKO mice stained with toluidine blue and
imaged at 20× magnification revealed inclusions (arrows) and centrally
located nuclei (arrowheads) within the muscle fibers of Mef2cSkMKO
mice following exercise (F).
Anderson et al. Skeletal Muscle  (2015) 5:7 Page 6 of 10mice had similar glycogen levels under baseline (No Run)
conditions (Figure 6A,B). However, control mice had a
slight drop in glycogen levels post-exercise (Figure 6C).
Remarkably, Mef2cSkMKO mice actually displayed an
increase in glycogen content in response to exercise
(Figure 6D, dark staining). Quantification of the glycogen
in the muscles of these mice, as determined by glycogen
precipitation and glucose release from glycogen, con-
firmed a significant increase in glycogen in Mef2cSkMKO
mice in response to exercise compared to control run
mice (Figure 6E). Taken together, these results demon-
strate that MEF2C is necessary for appropriate glycogen
metabolism in skeletal muscle in mice in response to
exercise.
MEF2C is required in skeletal muscle for normal glucose
homeostasis
The abnormal synthesis or metabolism of glycogen and
the overall smaller body size in Mef2cSkMKO mice sug-
gested that MEF2C function in skeletal muscle might be
important for normal whole body glucose homeostasis. To
test this hypothesis, we measured blood glucose in control
and Mef2cSkMKO mice after 16 h of fasting (Figure 7A). We
observed that Mef2cSkMKO mice had significantly lowerblood glucose levels compared to control mice (Figure 7A).
Furthermore, when mice were given a bolus injection of
glucose after 16 h of fasting, Mef2cSkMKO mice cleared the
glucose from their bloodstream more quickly than control
mice (Figure 7B). Taken together, these data suggest that
MEF2C is required in skeletal muscle for normal whole
body glucose metabolism and homeostasis.
Discussion
MEF2 proteins function as key transcriptional regulators
in skeletal muscle. Several metabolic genes have been
identified as direct targets of MEF2 [13,16,38], including
the genes encoding the glucose transporter GLUT4, the
master regulator of metabolism and mitochondrial bio-
genesis PGC-1α, and muscle creatine kinase, which is re-
quired for the production of ATP in skeletal muscle
[17,39-42]. In the present study, we found that MEF2C
is required in skeletal muscle for overall body growth,
Figure 6 Mef2c is required for normal glycogen utilization
in response to exercise. (A, B, C, D) Glycogen content was
qualitatively analyzed in the soleus muscle from exercised (Run) and
unexercised (No Run) control (ctl) and Mef2cSkMKO (cko) mice by
periodic acid Schiff’s (PAS) stain at 10× magnification. Arrowheads
depict regions of glycogen accumulation in exercised mice (C, D).
Red staining marks glycogen staining. (E) Glycogen concentration
was quantified by measuring the amount of glucose resulting from
the breakdown of glycogen in the gastrocnemius muscle from
unexercised (No Run) and exercised (Run) control and Mef2cSkMKO
mice. Mef2cSkMKO mice abnormally accumulated glycogen in muscle
in response to exercise compared to unexercised Mef2cSkMKO mice and
compared to exercised control mice, *p < 0.05. Data are presented as
milligrams of glucose per gram of muscle tissue used in the assay.
Values shown are mean + standard deviation, n = 9.
Figure 7 Mef2c function in skeletal muscle is required for normal
glucose homeostasis. Ten-week-old control (ctl) or Mef2cSkMKO (cko)
male mice were tested for glucose tolerance. (A) Following a 16-h fast
and prior to glucose injection, Mef2cSkMKO (cko) had significantly lower
blood glucose than control (ctl) mice, n = 12. (B) After a 16-h fast,
mice received a bolus injection of glucose (1 g glucose/kg body
weight) at time = 0. After an initial rise in blood glucose that resulted
in statistically identical blood glucose at t = 15 min, Mef2cSkMKO mice
cleared glucose from the blood more quickly than control mice,
n = 12. Blood glucose readings were taken at 0, 15, 30, 60, and 120 min
post-injection. *p < 0.05; **p < 0.01; ***p < 0.001. Values are
mean + standard deviation.
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function in skeletal muscle affects whole body size. Skel-
etal muscle is the primary tissue for insulin-stimulated
glucose uptake, disposal, and storage as glycogen for en-
ergy reserves [1,17]. Intriguingly, Mef2cSkMKO mice accu-
mulate more glycogen in skeletal muscle after exercise
compared to control mice. This result suggests that muscle
requires MEF2C function to induce a switch in substrate
utilization to glycogen such that in Mef2cSkMKO mice there
is an alteration of the glucose import and glycogen storage
pathways. Because Mef2cSkMKO mice have lower blood
sugar levels after fasting and clear glucose from the blood-
stream more quickly than control mice, our data suggest
that MEF2C-dependent pathways are important for main-
taining a normal balance between glucose and glycogen.The accumulation of glycogen in the skeletal muscle of
Mef2cSkMKO mice in response to exercise could be due to
importing too much glucose into the muscle during exer-
cise and then converting it to glycogen for storage [17].
Alternatively, MEF2C may be required to break down
glycogen to use as an energy source. Indeed, several genes
involved in glycogen metabolism, including those en-
coding GLUT4 and glycogen phosphorylase, have been
established as direct transcriptional targets of MEF2 or im-
plicated in MEF2-dependent gene regulation [40,43-45].
We examined the expression of several regulators of glu-
cose and glycogen metabolism that might account for the
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observed in Mef2cSkMKO mice, including genes encoding
GLUT1, GLUT4, glycogen phosphorylase, glycogen syn-
thase, phosphoinositide (PI) 3-kinase, and AMP kinase α2.
Surprisingly, however, no changes were observed in the
steady state mRNA level of any of the glucose or glycogen
regulatory genes that we examined in skeletal muscle at
baseline or in response to exercise (data not shown). Im-
portantly, other MEF2 proteins, most notably MEF2A and
MEF2D via their interactions with class II histone deacety-
lases and the CamKII pathway, are also associated with
glucose uptake in skeletal muscle [17], so a role for MEF2C
in glucose metabolism in skeletal muscle may involve com-
plex interactions with other MEF2 proteins.
Interestingly, deletion of the bHLH transcription factor
myogenin from skeletal muscle at either E15.5 or E17.5
results in smaller overall body size through an unknown
mechanism [46]. Myogenin interacts with MEF2C to acti-
vate skeletal muscle differentiation [47], suggesting the
possibility that MEF2C and myogenin may directly regu-
late genes necessary for proper glucose import and glyco-
gen storage, such as Glut4 or other genes associated with
insulin signaling.
Previous studies of mice lacking Mef2c in skeletal
muscle on an inbred C57BL/6 background demonstrated
lethality by postnatal day 2 due to abnormally formed, dis-
organized sarcomeres and weakened M lines [21]. In con-
trast, in the studies presented here, we found that mice
lacking Mef2c in skeletal muscle on an outbred back-
ground were viable and we observed no disorganization of
sarcomeres in Mef2c skeletal muscle knockouts. We be-
lieve that the most likely explanation for this discrepancy
is the difference in the genetic backgrounds of the mice in
the two studies. In support of this idea, Potthoff et al.
noted that inactivation of Mef2c in skeletal muscle on
other genetic backgrounds, such as 129/SvEv, resulted in a
less severe phenotype [23]. Another possible explanation
for the differences in viability of Mef2c skeletal muscle
knockout mice observed in the two studies might be sub-
tle differences in the Cre lines used. In the studies pre-
sented here, we used a transgenic mouse line in which Cre
is under the control of promoter and enhancer elements
from the Mef2c gene [24]. Potthoff et al. used a very simi-
lar Cre line, where Cre is under the control of the same 1
kb enhancer element from Mef2c fused to a 1.5 kb pro-
moter element from the myogenin gene [48]. Although
both these Cre lines exhibit tight skeletal muscle specifi-
city and appear to have highly similar patterns of activity
[24,48], subtle differences in the temporal or spatial pat-
tern of Cre expression or in its level of expression might
have influenced the precise degree ofMef2c excision. Con-
sistent with this possibility, Potthoff et al. found that in-
activation of Mef2c with MCK-Cre resulted in no evidence
of sarcomere disorganization, suggesting that relativelysubtle differences in Cre activity or pattern may also influ-
ence the severity of the phenotype observed in Mef2c con-
ditional knockout mice [21]. Importantly, however, no
metabolic or growth defects were reported in previous
studies of Mef2c loss-of-function in mice [21,23].
MEF2 proteins are important regulators of fiber type in
skeletal muscle. Using a multimerized MEF2-site dependent
reporter mouse line, Naya et al. demonstrated that MEF2
was constitutively active only in slow fibers [49]. Further-
more, dephosphorylation of MEF2 by calcineurin activates
MEF2 proteins and allows them to specifically activate the
slow muscle fiber genes encoding troponin I slow (TnIs)
and myoglobin (Mb) [34,35,50,51]. In addition, over ex-
pression of a constitutive activator form of MEF2C results
in increased formation of slow fibers [23]. Consistent with
these prior observations, we also found a requirement for
MEF2C in maintaining the appropriate proportion of slow
fibers in the soleus.
Overall, our studies demonstrate that MEF2C is re-
quired in skeletal muscle for the normal accumulation
and utilization of glycogen during exercise. This obser-
vation, combined with the requirement for MEF2C for
proper glucose uptake and clearance, supports a meta-
bolic role for MEF2C in skeletal muscle, where it is re-
quired for maintaining whole body energy homeostasis
and glucose metabolism. Increasing evidence implicates
skeletal muscle as a major contributor to the development
of insulin resistance, as muscle is the most abundant
insulin-sensitive tissue in the body [52]. Insulin resistance
leads to decreased insulin signaling and, in turn, leads to
decreased GLUT4 translocation and glucose transport,
which limits the fuel available to muscle for contraction
[17]. Impaired insulin signaling also causes abnormal
accumulation of lipids in skeletal muscle and reduced
mitochondrial function and reduced ATP production in
insulin-resistant muscle [2,53]. Because skeletal muscle is
crucial to maintaining normal insulin signaling and energy
production, it is important to understand the molecular
mechanisms underlying skeletal muscle metabolism. A de-
crease in slow fibers, increased glycogen storage, and a de-
crease in overall body size are all consistent with the
notion that mice lacking MEF2C in skeletal muscle use
energy less efficiently than wild type control mice. Given
the rapidly growing impact of diabetes and obesity, defin-
ing a role for MEF2C in skeletal muscle and whole body
metabolism will be of great help to further understand
metabolic disorders.
Conclusions
MEF2C is a critical regulator of nearly every aspect of skel-
etal muscle biology, yet its role in skeletal muscle metabol-
ism is incompletely understood, and previous genetic
studies have not identified a metabolic role for MEF2C.
Using as conditional knockout approach in mice, we found
Anderson et al. Skeletal Muscle  (2015) 5:7 Page 9 of 10that MEF2C is important for the slow fiber phenotype,
consistent with earlier studies. Moreover, we show that
mice lacking Mef2c in skeletal muscle have impaired over-
all body growth, display abnormal glycogen accumulation
in response to exercise, and have abnormal glucose me-
tabolism. Thus, these findings highlight a novel meta-
bolic function for MEF2C in skeletal muscle, where it is
required for glucose metabolism, glycogen utilization, and
energy homeostasis.
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